Study guide
Pain Management, Pharmacologic, and Integrative Care
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Pain Management, Pharmacologic, and Integrative Care
Key Takeaways Explain This Topic AI
The WHO analgesic ladder steps from nonopioids to opioids with adjuvants; cancer pain often requires scheduled long-acting opioids plus short-acting breakthrough doses.
Breakthrough rescue doses are typically about 10-20% of the total 24-hour oral morphine equivalent, given as immediate-release opioid.
Use equianalgesic conversions when switching opioids and reduce 25-50% for incomplete cross-tolerance; never give the full equianalgesic dose of the new drug.
Opioid-induced constipation is the most common opioid adverse effect (40% to 95% of patients) and is prevented with a scheduled stimulant laxative such as senna, not a stool softener; there is no analgesic ceiling for pure opioid agonists.
Integrative therapies (relaxation, imagery, music, acupuncture, massage) complement, never replace, analgesics; screen for bleeding, neutropenia, and supplement-drug interactions.
Last updated: October 2026
- Pain Management, Pharmacologic, and Integrative Care
- Pain Assessment
Cancer pain arises from tumor invasion, bone metastases, nerve compression, surgery, radiation, mucositis, procedures, lymphedema, and chemo-induced neuropathy. Assess location, intensity, quality, duration, pattern, aggravating and relieving factors, breakthrough episodes, current medications, allergies, renal and hepatic function, sedation, bowel pattern, sleep, mood, function, substance-use history, and the patient's acceptable pain goal . Use one scale consistently, but never reduce pain to a number, ask what the pain prevents the patient from doing.
New severe pain, pain with neurologic deficits, headache during thrombocytopenia, or pain at an infusion site may be an emergency.
- Pain type Examples Nursing focus
- Nociceptive somatic Bone, surgical pain Scheduled dosing, movement, fracture risk
- Visceral Liver capsule, bowel obstruction Associated nausea, distention, urgent signs
- Neuropathic Burning, shooting, numbness Adjuvants (gabapentin, duloxetine), fall prevention
- Breakthrough Flares despite baseline control Identify triggers, rescue dosing, reassess
- The WHO Ladder and Opioid Dosing
The WHO analgesic ladder guides selection: Step 1 nonopioids (acetaminophen, NSAIDs) +/- adjuvants; Step 2 weak opioids for mild-moderate pain; Step 3 strong opioids (morphine, hydromorphone, oxycodone, fentanyl) for moderate-severe pain, with adjuvants at every step. For persistent cancer pain, give a scheduled long-acting (around-the-clock) opioid plus a short-acting breakthrough (rescue) dose . The rescue dose is typically about 10-20% of the total 24-hour oral morphine equivalent , given as immediate-release. Pure opioid agonists have no ceiling dose , so the limit is set by side effects, not a maximum number.
When rotating opioids, use equianalgesic tables (for example, ~10 mg IV morphine ~ 30 mg oral morphine ~ 1.5 mg IV hydromorphone), then reduce the calculated new dose by 25-50% for incomplete cross-tolerance. Giving the full equianalgesic dose risks overdose. Reassess sooner for IV than oral routes.
Safety Monitoring and Constipation
Monitor for excessive sedation, confusion, slowed respirations, myoclonus, falls, nausea, pruritus, and urinary retention; sedation precedes clinically significant respiratory depression, so a rising sedation score is the early warning. Opioid-induced constipation is the most common opioid adverse effect (40% to 95% of patients), and patients generally do not develop tolerance to it: prevent it with a scheduled stimulant laxative such as senna, started with the opioid ; adding a stool softener offers no further benefit, and bulk-forming fiber alone can worsen impaction. Escalate uncontrolled or rapidly worsening pain, new neurologic findings, suspected fracture, severe sedation, or respiratory depression.
Refer to palliative care for complex or refractory pain.
Disease-Directed Options and Integrative Care
Some pain responds best when the driver is treated: bone-metastasis pain may improve with palliative radiation, bisphosphonates or denosumab , or orthopedic stabilization; neuropathic pain often needs adjuvants (gabapentin, pregabalin, duloxetine) rather than ever-higher opioids alone. Integrative modalities, relaxation breathing, guided imagery, music therapy, mindfulness, gentle movement, acupuncture, and adapted massage, can support coping, sleep, anxiety, and pain when used alongside prescribed care.
Safety rules: avoid massage over tumors, thrombosis, fragile skin, or severe thrombocytopenia; avoid acupuncture in severe neutropenia or thrombocytopenia without oncology approval; and ask nonjudgmentally about herbal supplements , which can interact with chemotherapy, anticoagulants, and anesthesia, routing questions to pharmacy. Patients underreport pain from fear of addiction, progression, or losing treatment; teach that early reporting prevents crises, and confirm dose timing, rescue limits, bowel regimen, and driving restrictions with teach-back.
Routes, Patient-Controlled Analgesia, and Special Situations
Route selection follows the pain pattern and the patient's ability to swallow. The oral route is preferred when feasible, but mucositis, obstruction, vomiting, or rapidly escalating pain may require IV, subcutaneous, or transdermal delivery. Transdermal fentanyl is reserved for opioid-tolerant patients with stable pain because it has a slow onset (12-24 hours to steady effect) and a long offset, making it unsafe for opioid-naive or unstable acute pain.
Patient-controlled analgesia (PCA) lets the patient self-administer small IV doses within preset limits; the nurse teaches that only the patient presses the button (never family members, which has caused fatal oversedation), monitors the sedation score and respiratory rate, and recognizes that the lockout interval and basal-versus-demand settings are prescriber decisions. Methadone has a long, variable half-life and complex equianalgesic conversion, so it is managed conservatively and usually by clinicians experienced with it.
Adjuvants, Tolerance, and Advocacy
Adjuvant analgesics treat pain that opioids alone manage poorly. Gabapentin, pregabalin, and duloxetine target neuropathic burning and shooting pain; corticosteroids reduce pain from nerve or spinal-cord compression and capsular stretch; bisphosphonates and denosumab reduce bone-metastasis pain and skeletal events. The nurse separates tolerance (needing more drug for the same effect), physical dependence (withdrawal if stopped abruptly), and addiction (compulsive use despite harm), because conflating them leads to undertreatment of legitimate cancer pain.
Patients on chronic opioids should taper rather than stop abruptly, and a sudden increase in opioid need usually signals disease progression or a new complication that deserves evaluation, not a label of drug-seeking. The nurse advocates by describing the pain pattern, functional impact, and medication response clearly, screening for diversion risk and safe storage and disposal without stigma, and confirming through teach-back that the patient understands the difference between the scheduled and rescue doses and exactly when to call for help.
Cultural beliefs, language, and prior experiences shape how patients express and treat pain, so the nurse assesses these factors and individualizes both the plan and the teaching rather than assuming a single approach fits everyone.